Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings

Merck reported Q2 2025 revenue of $15.81 billion, a 1.9% year-over-year decline, while its $2.13 EPS surpassed consensus estimates by 5.97%. Key product performance was mixed, with oncology drug Keytruda sales rising 9.4% to $7.96 billion and Janumet diabetes sales surging 300%, significantly offsetting a 54.6% year-over-year decline in Gardasil vaccine sales. Despite the overall revenue dip, Merck's shares have outperformed the S&P 500 over the past month.

Analysis

Merck's Q2 2025 financial results present a bifurcated picture, characterized by a significant bottom-line beat despite a top-line contraction. The company reported a 1.9% year-over-year revenue decline to $15.81 billion, marginally missing consensus estimates, while its earnings per share of $2.13 surpassed analyst expectations by a robust 5.97%. The divergence stems from varied performance across its product portfolio. The Oncology division remains the primary growth driver, with flagship drug Keytruda posting a 9.4% YoY sales increase to $7.96 billion, edging out estimates. This strength was complemented by solid performance in other oncology assets like Lynparza (+16.7% YoY) and a notable 11.1% YoY growth in the Animal Health segment. However, these gains were significantly counteracted by a severe 54.6% YoY plunge in Gardasil vaccine sales, which fell to $1.13 billion, well below the $1.3 billion consensus. Additionally, the new cardiovascular drug Winrevair recorded sales of $336 million, slightly trailing its initial analyst estimate of $343.79 million. Despite the mixed operational metrics, the stock has outperformed the S&P 500 over the past month, suggesting investors are currently prioritizing the strong EPS surprise over the headline revenue weakness.

Key Decisions for Investors

• Investors should assess whether the sustained growth in the Oncology portfolio, led by Keytruda's 9.4% year-over-year sales increase, is sufficient to compensate for major portfolio weaknesses, particularly the sharp 54.6% decline in Gardasil revenue.
• The slight miss on initial sales for the new cardiovascular drug Winrevair should be monitored closely in upcoming quarters, as its successful launch is a key factor in the company's long-term growth narrative beyond Keytruda.
• Given the conflicting signals of a strong 5.97% EPS beat against a 1.9% year-over-year revenue decline, it may be prudent to maintain a neutral position until there is more clarity on the stabilization of declining product lines and the growth trajectory of new assets.